Nav: Home

Infant model of HIV opens new avenues for research

September 05, 2019

Washington, DC - September 3, 2019 - Researchers have developed an animal model to test HIV infection and therapies in infants, allowing them to develop biomarkers to predict viral rebound after antiretroviral therapy (ART) interruption. The simian-human immunodeficiency virus (SHIV)-infected infant rhesus macaque model, a collaborative effort among researchers at several institutions, is described in a recent issue of the journal mBio.

"To date, all of the animal models that have been developed for studying novel therapies in nonhuman primate models around HIV have been in adult animals. A lot of those are immune based strategies, and we know that infants have a developing immune system that has distinct qualities," said study principal investigator Sallie Permar, MD, PHD, professor of pediatrics in the Division of Infectious Diseases; professor of molecular genetics and microbiology, immunology, and pathology; and member of Duke Human Vaccine Institute. "It is important to develop a model by which we can study infected infants and study the interventions that can be implemented to reduce the viral reservoir and delay time to rebound after stopping antiretroviral therapy."

The new model allows for immune interventions against the HIV envelope protein through the use of a SHIV, as opposed to a SIV, a simian immunodeficiency virus that has a very different virus envelope than HIV. Differences exist in the infant modes of HIV acquisition and immune responses, compared with adults or adolescents who become infected mostly through the sexual route. Moreover, this model takes advantage of recent advances in SHIV development that fully replicated the clade C viruses that are involved in the majority of infant HIV transmission. Researchers at the University of Pennsylvania have developed a new way to make SHIV, in which mutations are made around the CD4 binding site that HIV uses for entry into cells."This opened up a new treasure trove of SHIVs that would be available for this type of model," said Dr. Permar.

In the study, the researchers infected the infant monkeys with the new SHIV in the first one to two months of life, simulating a breast milk transmission. They then started the animals on antiretroviral therapy 12 weeks later and stopped treatment after a few months.They evaluated plasma virus load and found that the virus reached high peak virus load and responded quickly to therapy, which simulates what is seen in human infants.

The researchers then compared the viral replication kinetics and reservoir in infant rhesus macaques to that seen in a separate study of adult rhesus monkeys infected with the same SHIV strain. Infant monkeys had their virus rebound a couple of weeks after stopping the drugs, which was similar to adults, but adults had better virus control after rebound. "There are going to be differences in the infant and adult based therapies that are aimed at extending the time to viral rebound after stopping antiretroviral therapies," said the lead author of the study Ria Goswami, PHD, a postdoctoral associate at the Duke Human Vaccine Institute. "Novel interventions that do not rely on daily adherence to antiretroviral therapy are needed to achieve sustained viral remission for perinatally infected children, who currently rely on lifelong ART."

The researchers are already at work using the new model to test novel immune-based therapies, including monoclonal antibody therapies directed against the HIV envelope, to extend the time to virus rebound after stopping therapies. "A few years ago, a Mississippi baby who went on treatment quickly after delivery and exposure to HIV, and was then taken off therapy unintentionally, had no detectable virus for over two years. Eventually, the virus did return," said Dr. Permar."We are interested in how we can make it more likely to have more children like that."

When infants are started on HIV therapies in the earliest months of life and have to continue them lifelong, they are exposed to additive toxicities. "We are interested in having safer alternative strategies to antiretroviral drugs that will maintain virologic control for infected infants that are developed specifically for infants," said Dr. Permar."This is the first infant SHIV model to model HIV treatment and rebound."
The study was conducted by researchers at Duke University, in Durham, North Carolina; Emory University, in Atlanta, Georgia; University of North Carolina, in Chapel Hill, North Carolina; University of Pennsylvania, Philadelphia, Pennsylvania; and the University of California, in Davis, California.

The American Society for Microbiology is the largest single life science society, composed of more than 30,000 scientists and health professionals. ASM's mission is to promote and advance the microbial sciences.

ASM advances the microbial sciences through conferences, publications, certifications and educational opportunities. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to diverse audiences.

American Society for Microbiology

Related Hiv Articles:

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).
Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.
Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.
The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.
The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.
Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.
NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
First ever living donor HIV-to-HIV kidney transplant
For the first time, a person living with HIV has donated a kidney to a transplant recipient also living with HIV.
The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.
Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.
More HIV News and HIV Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at